Summary and Conclusions
A preliminary report in the use of Cytoxan in six patients with inoperable, far-advanced or recurrent adenocarcinoma of the large bowel is presented.
Two of the six patients had received the drug long enough for evaluation and both had apparent beneficial effects.
Further study of the effect of the drug in cases of carcinoma of the large bowel is required before significant conclusions can be reached.
Similar content being viewed by others
References
Arnold, Herbert, Friedrich Bourseaux and Norbert Brock: Neuartige Krebs-Chemotherapeutika aus der Gruppe der zyklischen N-Lost-Phosphamidester. Naturwissenschnften.45: 64, 1958.
Baumann, E.: Vorläufige Mitteilung über die Behandlung maligner Tumoren mit einem neuen N-Lost-Phosphamidester. Medizinische.14: 659, 1959.
Brock, N. Zur pharmakologischen Charackterisierung zyklischer N-Lost-Phosphamidester als Krebs-Chemotherapeutica. Arzneimittel-Forschung.8: 1, 1958.
Brock, N., and H. Wilmanns: Wirkung eines zyklischen N-Lost-Phosphamidesters auf experimentell erzeugte Tumoren der Ratte. Deutsche med. Wchnschr.83: 453, 1958.
Coggins, P. R., R. G. Ravdin, and S. H. Eisman: Clinical pharmacology and preliminary evaluation of Cytoxan (Cyclophosphamide). Cancer Chemotherapy Reports. U. S. Dept. of Health, Education and Welfare, Public Health Service, no. 3, June, 1959, p. 9.
Deddish, M. R.: Surgical procedures for carcinoma of the left colon and rectum, with five-year end results following abdominopelvic dissection of lymph nodes. Am. J. Surg.99: 188, 1960.
Dunphy, J. E.: Quoted by Crile, George, Jr.: Cancer and Common Sense. New York, Viking Press, 1955, p. 101.
Gross, Rudolf and Klaus Lambers: Erste Erfahrungen in der Behandlung maligner Tumoren mit einem neuen N-Lost-Phosphamidester. Deutsche med. Wchnschr.83: 458, 1958.
Lambers, K.: Behandlung der Lymphosarkome. Ärztl. Wchnschr.13: 692, 1958.
Mead Johnson & Company Brochure.
Petrides, P. and C. Moncke: Die Beeinflussung der Hamatopoese bei der Therapie von malignen Tumoren und Hamoblastosen mit einem N-Lost-Phosphamidester (Endoxan). Mitteilungsdienst der Gesellschaft zur Bekampfung der Krebskrankheiten Nordrhein Westfalen e.V., 2, no. 6, October, 1958.
Saitmacher, Heinz: Klinischer Erfahrungsbericht über ein neues Zytostatikum (Endoxan). Strahlentherapie.107: 94, 1958.
Author information
Authors and Affiliations
Additional information
Read at the meeting of the Pennsylvania Proctologic Society, May 18, 1960, Philadelphia, Pennsylvania.
Cytoxan is distributed in this country by Mead Johnson & Company.
About this article
Cite this article
Nuguid, T.P., Bacon, H.E. Management of inoperable carcinoma with particular reference to the use of cytoxan: Preliminary report. Dis Colon Rectum 4, 62–66 (1961). https://doi.org/10.1007/BF02616689
Issue Date:
DOI: https://doi.org/10.1007/BF02616689